Gibson Dunn has advised Avere Therapeutics. Cooley has advised the placement agents. Avere Therapeutics, Inc. (“Avere”), a privately-held biotechnology company, has announced a $500 million private...
Avere Therapeutics Secures $500 Million in Private Placement for Development of Once-Weekly Oral IL-23 Therapy
Avere Therapeutics and NextCure Announce Merger with $320 Million Private Placement
Gibson Dunn has advised Avere Therapeutics. Sidley Austin has advised NextCure. Avere Therapeutics, Inc., a privately-held biotechnology company, and NextCure, Inc. (Nasdaq:NXTC), a clinical-stage biopharmaceutical company,...
InMed Pharmaceuticals and Mentari Therapeutics Announce Merger and US$290 Million Private Placement to Accelerate Migraine Therapies
Gibson, Dunn & Crutcher LLP has advised Mentari Therapeutics, Inc. Norton Rose Fulbright LLP and Norton Rose Fulbright Canada LLP have advised InMed Pharmaceuticals, Inc. InMed...
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
Paul Hastings LLP has advised Ligand Pharmaceuticals Incorporated. Gibson Dunn has advised XOMA Royalty Corporation. Ligand Pharmaceuticals Incorporated has entered into a definitive agreement to acquire...
Korsana Biosciences and Cyclerion Therapeutics Announce All-Stock Merger and $380 Million Financing
Gibson Dunn has advised Korsana Biosciences. Ropes & Gray has advised Cyclerion Therapeutics. Korsana Biosciences and Cyclerion Therapeutics, Inc. have entered into a definitive agreement to...
Gyre Therapeutics Acquires Cullgen in $300 Million All-Stock Transaction
Gibson, Dunn & Crutcher LLP has advised Gyre Therapeutics, and Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. has advised Cullgen Inc. Gyre Therapeutics, Inc., an...
Yarrow Bioscience to Merge with VYNE Therapeutics in All-Stock Transaction
Gibson, Dunn & Crutcher LLP has advised Yarrow Bioscience. Cooley LLP has advised VYNE Therapeutics. Yarrow Bioscience and VYNE Therapeutics have entered into a definitive merger...
XenoTherapeutics and Xeno Acquisition Corp. Acquire Repare Therapeutics
Gibson Dunn and Blake, Cassels & Graydon LLP have advised XOMA Royalty. Cooley LLP and Stikeman Elliott LLP have advised Repare Therapeutics Inc. XenoTherapeutics, Inc. and...
Galecto Acquires Damora Therapeutics and Secures $285 Million PIPE Investment
Cleary Gottlieb has advised Viking Global Investors. Gibson Dunn has advised Damora Therapeutics. The acquisition of Damora Therapeutics Inc. by Galecto Inc. was completed alongside a...
Mural Oncology plc to Be Acquired by XRA 5 Corp (XOMA Royalty Corporation)
Arthur Cox has advised Mural Oncology plc. Gibson Dunn has advised XOMA Royalty Corporation and its subsidiary XRA 5 Corp. Mural Oncology plc has entered into...
XOMA Royalty to Acquire LAVA Therapeutics in Cash and Contingent Value Rights Deal
Gibson, Dunn & Crutcher LLP and Loyens & Loeff N.V. have advised XOMA Royalty Corporation on the transaction, while Cooley LLP and NautaDutilh N.V. as its...
RTW Investments Leads $85 Million Equity Offering by Aquestive Therapeutics
Gibson Dunn has advised RTW Investments, LP. , Dechert has advised Aquestive Therapeutics, Inc. and Cooley has advised the underwriters. RTW Investments, LP has acquired common...